Accelerating the Discovery, Development & Approval of First-In-Class Selective, Safe & Efficacious Degraders & Proximity-Based Drugs to Target the Undruggable
As the TPD field eagerly awaits the approval of Arvinas’s Vepdegestrant, and with C4 Therapeutics and Kymera progressing through Phase 1 and 2 clinical trials, 2025 is poised to be the year of clinical validation for TPD. This has been echoed in the flurry of partnerships worth over $200M in 2025 alone, with the majority of big pharma now invested in molecular glues, PROTACs, or novel induced proximity drugs.
Returning as the industry’s definitive forum from early discovery to clinical development, the 8th Annual TPD & Induced Proximity Summit is the world’s largest and longest-standing forum for proximity-based modalities, enabling you to fully immerse yourself in the breadth and depth of cutting-edge induced proximity therapeutic development.
Featuring key leaders such as Arvinas, Nurix Therapeutics, C4 Therapeutics, and innovative newcomers including Larkspur Bio, Magnet Biomedicine, TrimTech Therapeutics, as well as the co-founders of TPD, Craig Crews and Ray Deshaies, this is your ultimate meeting to hear the latest clinical data, forge strategic relationships, and capitalize on the huge opportunity for this modality to treat patients with high unmet clinical need.
Accommodation
Limited Rooms
Please note: As there is a Citywide taking place at the same time as the TPD Summit, our conference venue the Westin Boston Seaport District is fully booked during this period.
However, we are excited to announce that we have secured 2 room blocks in the Seaport area exclusively for attendees to secure discounted rates. We have limited availability and expect these to fill quickly, so we recommend to book as soon as possible.
Please see links below to book:
Announcing the Crews & Deshaies Award for the Induced Proximity Innovator of the Year
Get ready for the best TPD & Induced Proximity Summit to date—featuring the field’s original pioneers, Craig Crews and Ray Deshaies. Join us to hear their insights on where induced proximity is headed, the latest developments from the Crews lab, and celebrate the launch of the first-ever “Crews & Deshaies Award for the Induced Proximity Innovator of the Year” at the Annual TPD & Induced Proximity Awards. With Arvinas’s recent NDA submission marking what could be the first FDA-approved PROTAC, alongside exciting clinical advances from other leading players, 2025 is shaping up to be a landmark year for the field. There’s no better time to learn from the trailblazers who started it all.
Attending Companies Include














